Drugs / Novavax
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05658523 Comparator | Feb 2023 → Oct 2024 overdue | COVID-19 | Murdoch Childrens Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Novavax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05658523 ↗ |
| Modality | Vaccine | “Novavax COVID-19 protein subunit vaccine” NCT05658523 ↗ |